| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Harmine (telepathine) is a naturally occuring beta-carboline and fluorescent harmala alkaloid found in a number of different plants, most notably the Middle Eastern plant harmal or Syrian rue (Peganum harmala) and the South American vine Banisteriopsis caapi (formerly known as 'yage' or 'ayahuasca'). Harmine is a RIMA because it reversibly inhibits the enzyme monoamine oxidase A (MAO-A), which breaks down monoamines. While it does not inhibit the MAO-B variant, harmine binds to MAO-A specifically. In addition, it is an inhibitor of tyrosine phosphorylation-regulated kinase (DYRK) with anti-inflammatory and anti-cancer properties. With a Ki of 397 nM, harmine exhibits a high affinity for the 5-HT2A serotonin receptor.
| Targets |
5-HT2A Receptor (Ki = 397 nM); DYRK1A
|
|---|---|
| ln Vitro |
Harmine inhibits tau phosphorylation by DYRK1A by specific DANDYs, with an IC50 of 190 nM[2]. Harmine causes extreme cytotoxicity in hepatoma cells by disrupting Rad51 recruitment, which is how it negatively regulates homologous recombination (HR). Moreover, Hep3B cells are significantly more susceptible to the anti-proliferative effects of harmine when exposed to the NHEJ inhibitor Nu7441[3].
|
| ln Vivo |
It has been demonstrated that the TBI group has a noticeably higher brain water content. In comparison to the TBI group, treatment with harmine dramatically lowers the tissue water content at 1, 3, and 5 days. When comparing the escape latency at 3 and 5 days to the TBI group, the use of ammine treatment significantly lowers it. When compared to the TBI group that did not receive Harmine treatment, the motor function recovery of the rats is significantly improved by the administration of Harmine post-TBI at 1, 3, and 5 days post-TBI. In comparison with the TBI group, the neuronal survival rate is markedly higher in the group treated with harmine. When Harmine is administered, compared to the TBI group, there is a noticeable increase in GLT-1 expression. In contrast to the TBI group, the administration of harmine dramatically lowers caspase 3 expression[4].
|
| Cell Assay |
Experiments on DNA damage, cell death, and proliferation are carried out using the High Content Screening (HCS) format. A multiwell 384 µClear plate coated with 100 µg/mL Poly-L-ornithine and 10 µg/mL laminin is used to plate the hNPCs (1,500 cells/per well). Following a 24-hour period, cells are treated with harmine, INDY, and pargyline in quintuplicate (five wells per condition) for four days in N2B27 medium supplemented with bFGF and EGF. Day 4: 30 minutes before fixation or image acquisition, cells are labeled with 10 µM EdU for cell proliferation or BOBO™ -3 for cell death.
|
| Animal Protocol |
Rats: The study uses 150 male Sprague-Dawley rats, weighing between 280 and 320 g and aged between 10 and 12 weeks. Three groups of rats are randomly assigned: the TBI group (n=35); the TBI + Harmine-treated group (n=35); and the Sham-operated group (n= 15). Immediately after traumatic brain injury, heroine (i.p., 30 mg/kg daily) is given for a maximum of five days. Equal volumes of 0.9% saline solution are given to the TBI and sham groups (i.p.). For the purpose of examining behavioral recovery, the rats are divided into three groups: Sham (n = 3), TBI (n = 7), and Harmine (n = 7). The NSS is assessed 1, 3, and 5 days after a traumatic brain injury. An observer who is blind to the animal treatment evaluates each rat individually[4].
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Harmine has known human metabolites that include 6-Hydroxy-harmaline and Harmol. |
| References |
|
| Additional Infomation |
Harmine is a harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7. It has a role as a metabolite, an anti-HIV agent and an EC 1.4.3.4 (monoamine oxidase) inhibitor. It derives from a hydride of a harman.
Harmine has been reported in Passiflora phoenicia, Symplocos setchuensis, and other organisms with data available. Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's. |
| Molecular Formula |
C13H12N2O
|
|---|---|
| Molecular Weight |
212.2472
|
| Exact Mass |
212.094
|
| Elemental Analysis |
C, 73.56; H, 5.70; N, 13.20; O, 7.54
|
| CAS # |
442-51-3
|
| Related CAS # |
Harmine hydrochloride;343-27-1
|
| PubChem CID |
5280953
|
| Appearance |
White to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
421.4±40.0 °C at 760 mmHg
|
| Melting Point |
262-264 °C(lit.)
|
| Flash Point |
139.8±17.0 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.706
|
| LogP |
3.17
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
16
|
| Complexity |
258
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C1C([H])=C([H])C2=C(C=1[H])N([H])C1C(C([H])([H])[H])=NC([H])=C([H])C2=1
|
| InChi Key |
BXNJHAXVSOCGBA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H12N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-7,15H,1-2H3
|
| Chemical Name |
7-methoxy-1-methyl-9H-pyrido[3,4-b]indole
|
| Synonyms |
Harmine; telepathine; Yageine; 7-Methoxy-1-methyl-9H-pyrido[3,4-b]indole; Banisterine; Telepathine; Leucoharmine; Yajeine; Banisterine; Leucoharmine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 30 mg/mL (~141.3 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7114 mL | 23.5571 mL | 47.1143 mL | |
| 5 mM | 0.9423 mL | 4.7114 mL | 9.4229 mL | |
| 10 mM | 0.4711 mL | 2.3557 mL | 4.7114 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05526430 | Completed | Drug: Harmine Hydrochloride Capsules |
Diabetes Mellitus | James Murrough | September 13, 2022 | Phase 1 |
| NCT04716335 | Completed | Drug: DMT Drug: Harmine |
Emotions Mood |
Psychiatric University Hospital, Zurich |
December 1, 2020 | Early Phase 1 |
| NCT05780216 | Completed | Drug: DMT + harmine Drug: Placebo |
Healthy Participants | Milan Scheidegger | February 20, 2023 | Early Phase 1 |
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
